Evidence map›Paper›PMID 34052834›Full record

ArticleTranslational psychiatry2021

Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.

Erik D Fagerholm, Robert Leech, Steven Williams, Carlos A Zarate, Rosalyn J Moran, Jessica R Gilbert

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  4. Review
  5. Aperiodic Signatures of Stress Sensitivity and Depression Recurrence in Adolescents.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Article
  6. Article
  7. Review
  8. Esketamine in depression: putative biomarkers from clinical research.European archives of psychiatry and clinical neuroscience · 2025
    Review
  9. Article
  10. Measuring neuroplasticity in human development: the potential to inform the type and timing of mental health interventions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  11. Review
  12. Glutamate modulators and beyond: A neuroscience revolution in the making.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Erik D FagerholmDepartment of Neuroimaging, King's College London, London, UK. erik.fagerholm@kcl.ac.uk.ORCID 0000-0003-2973-1395
Robert LeechDepartment of Neuroimaging, King's College London, London, UK.
Steven WilliamsDepartment of Neuroimaging, King's College London, London, UK.ORCID 0000-0003-4299-1941
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD, USA.
Rosalyn J Moran *Department of Neuroimaging, King's College London, London, UK.
Jessica R Gilbert *Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD, USA. jessica.gilbert@nih.gov.ORCID 0000-0002-4194-6172
King's College London · GBNational Institutes of Health · US

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Glutamatergic Modulators--Rapid Sustained AntidepressantZ01MH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MANJI, HUSSEINI K · 2005 to 2008
$621k
Intramural NIH HHS Z01 MH002857Intramural NIH HHS ZIA MH002857Medical Research Council MR/R005370/1Wellcome Trust
6 · The paper itself

Abstract

The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment response. Here, we analyse neuromagnetic virtual electrode time series collected from the primary somatosensory cortex in 18 unmedicated patients with TRD and in an equal number of age-matched healthy controls during a somatosensory 'airpuff' stimulation task. These two groups were scanned as part of a clinical trial of ketamine efficacy under three conditions: (a) baseline; (b) 6-9 h following subanesthetic ketamine infusion; and (c) 6-9 h following placebo-saline infusion. We obtained estimates of E/I interaction strengths by using dynamic causal modelling (DCM) on the time series, thereby allowing us to pinpoint, under each scanning condition, where each subject's dynamics lie within the Poincaré diagram-as defined in dynamical systems theory. We demonstrate that the Poincaré diagram offers classification capability for TRD patients, in that the further the patients' coordinates were shifted (by virtue of ketamine) toward the stable (top-left) quadrant of the Poincaré diagram, the more their depressive symptoms improved. The same relationship was not observed by virtue of a placebo effect-thereby verifying the drug-specific nature of the results. We show that the shift in neural dynamics required for symptom improvement necessitates an increase in both excitatory and inhibitory coupling. We present accompanying MATLAB code made available in a public repository, thereby allowing for future studies to assess individually tailored treatments of TRD.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineMajor Depressive DisorderDepressionExcitatory Amino Acid AntagonistsHumansInfusions, IntravenousTreatment OutcomeExcitatory Amino Acid AntagonistsKetamine

Identifiers

PMID34052834
PMCPMC8164631
OpenAlexW3128669940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.